Long Grove Pharmaceuticals Launches Generic Dalbavancin for Injection

Long Grove Pharmaceuticals received FDA approval for the generic version of dalbavancin for injection. Dalbavancin for injection is an antibiotic bioequivalent to Dalvance (Abbvie) and was originally approved in 2014 for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; wid